# Formula N-5550: Advanced Multi-Target Cognitive Enhancement

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. COMPOSITION & OVERVIEW

Formula N-5550 is a sophisticated, multi-target cognitive enhancement protocol designed to improve memory, focus, and mental clarity while also supporting weight management. It combines three distinct but complementary agents that modulate neurotropic, metabolic, and mitochondrial pathways.

| Component | Dosage | Primary Mechanism |
|---|---|---|
| **Dihexa** | 5 mg | HGF/c-Met System Activation & Structural Synaptogenesis |
| **Tesofensine** | 0.5 mg | Triple Monoamine (Serotonin, Norepinephrine, Dopamine) Reuptake Inhibitor |
| **Methylene Blue** | 50 mg | Mitochondrial Redox Cycling & MAO Inhibition |

This formulation provides a powerful combination of structural neural enhancement, neurochemical optimization, and improved cellular energy production, making it a comprehensive tool for cognitive and metabolic support.

---

## 2. DETAILED MECHANISM OF ACTION

Formula N-5550 leverages a triple-pathway approach to cognitive and metabolic enhancement.

### 2.1 Dihexa: Neurotropic Pathway & Structural Plasticity

Dihexa is a potent, blood-brain barrier-permeable peptide analog of Angiotensin IV. It functions by potentiating the Hepatocyte Growth Factor (HGF)/c-Met signaling system, which is crucial for neuronal growth, survival, and repair [1].

- **Synaptogenesis:** By activating the c-Met receptor, Dihexa promotes robust synaptogenesis, leading to the formation of new functional synaptic connections and increasing the structural capacity of neural networks for information processing.
- **Cognitive Enhancement:** In animal models of Alzheimer's disease, Dihexa has been shown to rescue cognitive deficits and improve spatial memory, effects mediated by the PI3K/AKT signaling pathway downstream of c-Met activation [1].

### 2.2 Tesofensine: Neurochemical & Metabolic Pathway

Tesofensine is a triple monoamine reuptake inhibitor, blocking the presynaptic reuptake of serotonin, norepinephrine, and dopamine. This increases the synaptic availability of these key neurotransmitters, which are vital for mood, focus, motivation, and appetite regulation.

- **Cognitive Effects:** The elevation of dopamine and norepinephrine in the prefrontal cortex enhances executive functions, including attention, working memory, and cognitive flexibility.
- **Metabolic Effects:** Originally developed for neurodegenerative diseases, Tesofensine was found to produce significant weight loss in clinical trials. A Phase II study published in *The Lancet* showed that a 0.5 mg dose produced a placebo-adjusted weight loss of 9.2% over 24 weeks [2]. This effect is primarily driven by a reduction in appetite and an increase in resting energy expenditure.

### 2.3 Methylene Blue: Mitochondrial & Neurochemical Pathway

Methylene Blue (MB) is a unique compound with a long history of medical use. At low doses, it acts as a powerful metabolic enhancer and nootropic.

- **Mitochondrial Redox Cycling:** MB can accept electrons from NADH at Complex I of the electron transport chain and donate them to Cytochrome C. This creates an alternative electron transfer pathway, bypassing potential blockages, increasing ATP production, and reducing oxidative stress [3].
- **Monoamine Oxidase (MAO) Inhibition:** MB is a potent, reversible inhibitor of Monoamine Oxidase-A (MAO-A), the enzyme responsible for breaking down serotonin and norepinephrine. This action synergizes with Tesofensine, further increasing the levels of these key neurotransmitters [4].

### 2.4 Synergistic Architecture

The synergy of Formula N-5550 is profound. Dihexa provides the long-term structural foundation for enhanced cognition. Tesofensine and Methylene Blue work in concert to dramatically increase the key monoamine neurotransmitters that drive focus, mood, and motivation. Simultaneously, Methylene Blue optimizes the very core of cellular function—mitochondrial energy production—while Tesofensine provides a powerful secondary benefit of appetite suppression and weight management.

---

## 3. CLINICAL INDICATIONS & BENEFITS

Formula N-5550 is indicated for individuals seeking significant cognitive enhancement, improved mood and focus, and support for weight management goals.

| Category | Key Benefits |
|---|---|
| **Cognitive Enhancement** | Improved memory, focus, and mental clarity; enhanced executive function and processing speed. |
| **Metabolic & Weight** | Significant appetite suppression; increased resting energy expenditure; clinically significant weight loss. |
| **Mood & Energy** | Elevated mood and motivation; increased mental and physical energy; reduced brain fog. |
| **Neuroprotection** | Promotion of neural plasticity and resilience; protection against oxidative stress. |

---

## 4. DOSING, ADMINISTRATION & SAFETY

- **Standard Dose:** One capsule daily, preferably in the morning to avoid sleep disruption.
- **Administration:** Can be taken with or without food.
- **Safety Profile:** Generally well-tolerated. Tesofensine can increase heart rate and blood pressure. Methylene Blue can cause urine and sclera to turn blue/green, which is a harmless side effect. It is a potent MAO-A inhibitor and carries a risk of serotonin syndrome if combined with other serotonergic drugs.
- **Contraindications:** Use of SSRIs, SNRIs, or other MAOIs; severe cardiovascular disease; pregnancy/lactation.
- **Drug Interactions:** High risk of serotonin syndrome when combined with other serotonergic agents. Patients should have a 2-4 week washout period from other serotonergic medications before starting.

---

## 5. REFERENCES

[1] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487. [https://doi.org/10.3390/brainsci11111487](https://doi.org/10.3390/brainsci11111487)

[2] Astrup, A., et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 372(9653), 1906-1913. [https://doi.org/10.1016/S0140-6736(08)61525-1](https://doi.org/10.1016/S0140-6736(08)61525-1)

[3] Rojas, J. C., & Gonzalez-Lima, F. (2013). Low-dose methylene blue: a novel and promising neuroprotective agent for neurodegenerative disorders. *Molecular Neurobiology*, 48(3), 525-535. [https://doi.org/10.1007/s12035-013-8465-9](https://doi.org/10.1007/s12035-013-8465-9)

[4] Ramsay, R. R., et al. (2007). A site-directed inhibitor of monoamine oxidase: Methylene blue. *Journal of Neural Transmission*, 114(6), 783-786. [https://doi.org/10.1007/s00702-007-0739-2](https://doi.org/10.1007/s00702-007-0739-2)
